MedTrace Logo

The Impact of C-reactive Protein Testing

NCT02758821 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 2410

Last updated 2018-08-15

No results posted yet for this study

Summary

PRIMARY OBJECTIVE To assess the impact of C-reactive protein (CRP) Point-of-care (POC) testing on health care worker prescribing behaviour in patients presenting to primary healthcare centres with an acute fever or recent history of fever.

SECONDARY OBJECTIVES To assess the impact of CRP testing on clinical outcomes within the 14 days of follow-up.

To assess the correlation between CRP results and clinical outcomes on the day 5 of the enrolment.

To estimate the impact of CRP testing on antibiotic consumption after first consultation.

To explore the attitudes of health centre staff towards the POC CRP test. To identify the prevalence of key pathogens in febrile patients in these settings.

To validate the ability of CRP to discriminate between viral and bacterial pathogens in a subset of patients with a microbiologically confirmed diagnosis.

Conditions

Interventions

OTHER

No CRP will be measured onsite

No CRP will be measured onsite

OTHER

CRP cut-off of 20mg/L.

Health care worker will be given an advice to prescribe antibiotic to patient who has CRP lever \< 20mg/L.

OTHER

CRP cut-off of 40mg/L.

Health care worker will be given an advice to prescribe antibiotic to patient who has CRP lever \< 40mg/L.

Sponsors & Collaborators

  • Department of Medical Research, Lower Myanmar

    collaborator OTHER

  • University of Oxford

    lead OTHER

Principal Investigators

  • Yoel Lubell, MD · Mahidol Oxford Tropical Medicine Research Unit

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
1 Year
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-06-08
Primary Completion
2017-09-30
Completion
2017-09-30

Countries

  • Thailand

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02758821 on ClinicalTrials.gov